<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>OTCGREY-Listed — Portfolio on 6ix</title>
<link>https://6ix.com/p/otcgrey-listed</link>
<description>Top companies trading on OTCGREY, ranked by market cap.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 06:51:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/portfolio/otcgrey-listed" rel="self" type="application/rss+xml" />
<item>
<title>Elkem Asa: Elkem: First quarter 2026 - Strategic transformation and strengthening financial resilience</title>
<link>https://6ix.com/company/elkem-asa/news/elkem-first-quarter-2026-strategic-transformation-and-strengthening-financial-resilience</link>
<guid isPermaLink="true">https://6ix.com/company/elkem-asa/news/elkem-first-quarter-2026-strategic-transformation-and-strengthening-financial-resilience</guid>
<pubDate>Thu, 30 Apr 2026 06:51:00 GMT</pubDate>
<description>Elkem reported an EBITDA of NOK 249 million for the first quarter 2026, which was a decrease from NOK 710 million in the corresponding quarter last year. The reduction was mainly explained by production curtailments at multiple plants in Norway. Elkem expects to conclude the sale of the Silicones division today. Divesting the Silicones business will sharpen Elkem's strategic focus and tighten capital allocation. Elkem will conduct a guaranteed equity offering of NOK 1 500 million with a subseque</description>
</item>
<item>
<title>Argen-x: argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026</title>
<link>https://6ix.com/company/argen-x/news/argenx-to-report-first-quarter-2026-financial-results-and-business-update-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-to-report-first-quarter-2026-financial-results-and-business-update-on-may-7-2026</guid>
<pubDate>Thu, 30 Apr 2026 05:00:00 GMT</pubDate>
<description>April 30, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com</description>
</item>
<item>
<title>Landis+gyr Group Ag: Landis+Gyr Announces Sale of Rhebo to Everfield</title>
<link>https://6ix.com/company/landisgyr-group-ag/news/landisgyr-announces-sale-of-rhebo-to-everfield</link>
<guid isPermaLink="true">https://6ix.com/company/landisgyr-group-ag/news/landisgyr-announces-sale-of-rhebo-to-everfield</guid>
<pubDate>Thu, 30 Apr 2026 04:45:00 GMT</pubDate>
<description>Landis+Gyr Group AG (SIX: LAND), a global energy technology leader driving intelligent innovation across the grid, today announced it has signed a definitive agreement to sell Rhebo GmbH to Everfield Germany GmbH, a buy-and-hold investor in European B2B SaaS businesses. Completion of the transaction remains subject to customary regulatory approvals and other standard closing conditions.</description>
</item>
<item>
<title>Métropole Télévision S.a.: M6 METROPOLE TELEVISION: First Quarter 2026 Financial Information</title>
<link>https://6ix.com/company/metropole-television-sa/news/m6-metropole-television-first-quarter-2026-financial-information-1</link>
<guid isPermaLink="true">https://6ix.com/company/metropole-television-sa/news/m6-metropole-television-first-quarter-2026-financial-information-1</guid>
<pubDate>Tue, 28 Apr 2026 10:05:00 GMT</pubDate>
<description>NEUILLY-SUR-SEINE, France, April 28, 2026--Regulatory News: M6 METROPOLE TELEVISION (Paris:MMT):</description>
</item>
<item>
<title>Edreams Odigeo Sa: eDreams ODIGEO Exceeds Subscriber Growth Target by 5% and Reaches 7.9 Million Prime Members</title>
<link>https://6ix.com/company/edreams-odigeo-sa/news/edreams-odigeo-exceeds-subscriber-growth-target-by-5percent-and-reaches-79-million-prime-members</link>
<guid isPermaLink="true">https://6ix.com/company/edreams-odigeo-sa/news/edreams-odigeo-exceeds-subscriber-growth-target-by-5percent-and-reaches-79-million-prime-members</guid>
<pubDate>Tue, 28 Apr 2026 08:34:00 GMT</pubDate>
<description>BARCELONA, Spain, April 28, 2026--eDreams ODIGEO (the "Company" or "eDO") (BME: EDR) (OTC: EDDRF) the world’s leading travel subscription company, today provides an operating update regarding its Prime membership growth for the fiscal year ended 31 March 2026. [This update focuses exclusively on the Prime subscriber target; comprehensive financial results for fiscal year 2026 will be reported during the Company’s standard earnings cycle at the usual time.]</description>
</item>
<item>
<title>Valmet Oyj: Valmet to start change negotiations regarding temporary layoffs in Finland</title>
<link>https://6ix.com/company/valmet-oyj/news/valmet-to-start-change-negotiations-regarding-temporary-layoffs-in-finland-2</link>
<guid isPermaLink="true">https://6ix.com/company/valmet-oyj/news/valmet-to-start-change-negotiations-regarding-temporary-layoffs-in-finland-2</guid>
<pubDate>Tue, 28 Apr 2026 06:37:00 GMT</pubDate>
<description>Valmet will start change negotiations in Finland in accordance with the Finnish Co-operation Act on May 4, 2026. The plan under negotiations may include temporary layoffs of less than 90 days.</description>
</item>
<item>
<title>Valmet Oyj: Valmet Oyj's Interim Review January 1 - March 31, 2026: Strategy execution progressed in the first quarter, while sales mix impacted the results</title>
<link>https://6ix.com/company/valmet-oyj/news/valmet-oyjs-interim-review-january-1-march-31-2026-strategy-execution-progressed-in-the-first-quarter-while-sales-mix-impacted-the-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/valmet-oyj/news/valmet-oyjs-interim-review-january-1-march-31-2026-strategy-execution-progressed-in-the-first-quarter-while-sales-mix-impacted-the-results-1</guid>
<pubDate>Tue, 28 Apr 2026 06:24:00 GMT</pubDate>
<description>Valmet Oyj's Interim Review January 1 - March 31, 2026: Strategy execution progressed in the first quarter, while sales mix impacted the results</description>
</item>
<item>
<title>Conduit Holdings Ltd: Notice of Q1 2026 Trading Update</title>
<link>https://6ix.com/company/conduit-holdings-ltd/news/notice-of-q1-2026-trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/conduit-holdings-ltd/news/notice-of-q1-2026-trading-update</guid>
<pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
<description>Conduit Holdings Limited announced that its first quarter 2026 trading update for the period ending March 31, 2026, will be released on Wednesday, May 13, 2026. Management will host virtual presentations for analysts and investors on the same day at 12:00 pm UK time, followed by a separate presentation for retail investors via the Investor Meet Company platform at 4:00 pm UK time. No new financial information will be disclosed during the retail investor presentation.
Disclaimer*</description>
</item>
<item>
<title>Ondine Biomedical Inc: ICU Study to be Presented at 2026 CACCN Conference</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/icu-study-to-be-presented-at-2026-caccn-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/icu-study-to-be-presented-at-2026-caccn-conference</guid>
<pubDate>Mon, 27 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that findings from its Steriwave ICU study, demonstrating a 39.5% reduction in pneumonia rates and significant pathogen reduction with no adverse events, have been selected for oral and poster presentation at the Canadian Critical Care Nursing Conference. This study, the first deployment of nasal photodisinfection in an ICU setting, highlights the non-antibiotic Steriwave therapy's potential to reduce healthcare-associated infections and address antimicrobial res</description>
</item>
<item>
<title>Ecn Capital Corp: ECN Capital Announces Closing of Acquisition by Investor Group Led by Warburg Pincus and Goodview Capital</title>
<link>https://6ix.com/company/ecn-capital-corp/news/ecn-capital-announces-closing-of-acquisition-by-investor-group-led-by-warburg-pincus-and-goodview-capital</link>
<guid isPermaLink="true">https://6ix.com/company/ecn-capital-corp/news/ecn-capital-announces-closing-of-acquisition-by-investor-group-led-by-warburg-pincus-and-goodview-capital</guid>
<pubDate>Fri, 24 Apr 2026 18:15:00 GMT</pubDate>
<description>ECN Capital Corp. (TSX: ECN) ("ECN Capital" or the "Company") announced today the successful completion of the Company's previously announced plan of arrangement (the "Arrangement") whereby a newly formed acquisition vehicle controlled by an investor group led by investment funds managed by Warburg Pincus LLC and including Goodview Capital Corp. (the "Purchaser") acquired (i) all of the issued and outstanding common shares of the Company (the "Common Shares") for C$3.10 in cash per Common Share;</description>
</item>
<item>
<title>Getlink Se: Mundys Exercises Its Right to Acquire up to 25.0% of the Share Capital and 29.9% of the Voting Rights of Getlink</title>
<link>https://6ix.com/company/getlink-se/news/mundys-exercises-its-right-to-acquire-up-to-250percent-of-the-share-capital-and-299percent-of-the-voting-rights-of-getlink</link>
<guid isPermaLink="true">https://6ix.com/company/getlink-se/news/mundys-exercises-its-right-to-acquire-up-to-250percent-of-the-share-capital-and-299percent-of-the-voting-rights-of-getlink</guid>
<pubDate>Fri, 24 Apr 2026 18:00:00 GMT</pubDate>
<description>ROME, April 24, 2026--Regulatory News: Following the previous announcements released on 31 March 2026 and 13 April 2026, Mundys1 has entirely exercised its right to increase its shareholding in Getlink up to 25.0% of the share capital and 29.9% of the voting rights2.</description>
</item>
<item>
<title>Copper Property Ctl Pass Through Trust: Copper Property CTL Pass Through Trust Termination Date Extended</title>
<link>https://6ix.com/company/copper-property-ctl-pass-through-trust/news/copper-property-ctl-pass-through-trust-termination-date-extended</link>
<guid isPermaLink="true">https://6ix.com/company/copper-property-ctl-pass-through-trust/news/copper-property-ctl-pass-through-trust-termination-date-extended</guid>
<pubDate>Fri, 24 Apr 2026 16:43:00 GMT</pubDate>
<description>JERSEY CITY, N.J., April 24, 2026--Copper Property CTL Pass Through Trust ("the Trust") has filed a Form 14-C announcing that the Trust Agreement has been amended to extend the Trust Termination Date by 60 days to June 29, 2026, by written consent of the majority of the Certificateholders.</description>
</item>
<item>
<title>Munters Group Ab: Munters wins order of BSEK 2.0 for a modular AI cooling solution</title>
<link>https://6ix.com/company/munters-group-ab/news/munters-wins-order-of-bsek-20-for-a-modular-ai-cooling-solution</link>
<guid isPermaLink="true">https://6ix.com/company/munters-group-ab/news/munters-wins-order-of-bsek-20-for-a-modular-ai-cooling-solution</guid>
<pubDate>Fri, 24 Apr 2026 06:21:00 GMT</pubDate>
<description>Munters business area Data Center Technologies (DCT) has received an order worth appr. BSEK 2.0 from a colocation data center provider in the US. The order includes custom-designed high capacity CDUs (coolant distribution units) and over the rack CRAHs (computer room air handlers) with deliveries expected to start in early 2027 and extend through the first quarter of 2028.</description>
</item>
<item>
<title>Jde Peets Nv: JDE PEET’S N.V. announces consent solicitations in respect of outstanding Euro Notes</title>
<link>https://6ix.com/company/jde-peets-nv/news/jde-peets-nv-announces-consent-solicitations-in-respect-of-outstanding-euro-notes</link>
<guid isPermaLink="true">https://6ix.com/company/jde-peets-nv/news/jde-peets-nv-announces-consent-solicitations-in-respect-of-outstanding-euro-notes</guid>
<pubDate>Fri, 24 Apr 2026 06:00:00 GMT</pubDate>
<description>PRESS RELEASE Amsterdam, April 24, 2026 Not for release, publication or distribution in or into, or to any person located or resident in, any jurisdiction where it is unlawful to release, publish or distribute this document. JDE Peet’s N.V. (the "Issuer") announces today separate invitations (each such invitation, a "Consent Solicitation") to eligible holders of each Series of the outstanding Notes to consent to certain modifications of the terms and conditions (in respect of each Series, the "C</description>
</item>
<item>
<title>Ondine Biomedical Inc: Marked Reduction in SSIs at Ottawa Heart Institute</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/marked-reduction-in-ssis-at-ottawa-heart-institute</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/marked-reduction-in-ssis-at-ottawa-heart-institute</guid>
<pubDate>Thu, 23 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that the University of Ottawa Heart Institute observed a statistically significant reduction in surgical site infections among cardiac surgery patients after implementing Steriwave nasal decolonisation into their presurgical protocols, comparing an eight-month pilot program with Steriwave against a prior 24-month control period using mupirocin. These positive findings, which are expected to be presented at a major international cardiac conference and detailed in </description>
</item>
<item>
<title>Getlink Se: Getlink SE: First Quarter 2026: Revenue up 15%</title>
<link>https://6ix.com/company/getlink-se/news/getlink-se-first-quarter-2026-revenue-up-15percent</link>
<guid isPermaLink="true">https://6ix.com/company/getlink-se/news/getlink-se-first-quarter-2026-revenue-up-15percent</guid>
<pubDate>Thu, 23 Apr 2026 05:30:00 GMT</pubDate>
<description>PARIS, April 23, 2026--Regulatory News: Getlink SE (Paris:GET):</description>
</item>
<item>
<title>Galderma Group N: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-reports-strong-start-to-the-year-delivering-first-quarter-2026-net-sales-of-1473-billion-usd-growing-255percent-at-constant-currency</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-reports-strong-start-to-the-year-delivering-first-quarter-2026-net-sales-of-1473-billion-usd-growing-255percent-at-constant-currency</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland, April 23, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026.</description>
</item>
<item>
<title>Ascom Holding Ag: Laurent Dubois elected as new Chairman of the Board of Directors of Ascom</title>
<link>https://6ix.com/company/ascom-holding-ag/news/laurent-dubois-elected-as-new-chairman-of-the-board-of-directors-of-ascom</link>
<guid isPermaLink="true">https://6ix.com/company/ascom-holding-ag/news/laurent-dubois-elected-as-new-chairman-of-the-board-of-directors-of-ascom</guid>
<pubDate>Wed, 22 Apr 2026 16:02:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, April 22, 2026At the Annual General Meeting held on April 22, 2026, in Zug, the shareholders of Ascom Holding AG approved all proposals from the Board of Directors by a large majority. 66 shareholders attended the Annual General Meeting. In total, 17’690’637 registered shares with voting rights were represented, corresponding to 49.14 % of the share capital. The annual financial statements and consolidated financial statements for the</description>
</item>
<item>
<title>Galderma Group N: Galderma Shareholders Approve All Annual General Meeting Proposals</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-shareholders-approve-all-annual-general-meeting-proposals</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-shareholders-approve-all-annual-general-meeting-proposals</guid>
<pubDate>Wed, 22 Apr 2026 15:45:00 GMT</pubDate>
<description>ZUG, Switzerland, April 22, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions.</description>
</item>
<item>
<title>Bmo Ultra Short Term Us Bond Etf: BMO Announces Cash Distributions for Certain BMO ETFs and ETF Series of BMO Mutual Funds for April 2026</title>
<link>https://6ix.com/company/bmo-ultra-short-term-us-bond-etf/news/bmo-announces-cash-distributions-for-certain-bmo-etfs-and-etf-series-of-bmo-mutual-funds-for-april-2026-54</link>
<guid isPermaLink="true">https://6ix.com/company/bmo-ultra-short-term-us-bond-etf/news/bmo-announces-cash-distributions-for-certain-bmo-etfs-and-etf-series-of-bmo-mutual-funds-for-april-2026-54</guid>
<pubDate>Wed, 22 Apr 2026 11:30:00 GMT</pubDate>
<description>BMO Asset Management Inc., as manager of the BMO ETFs, and BMO Investments Inc., as manager of the BMO Mutual Funds, today announced the April 2026 cash distributions for unitholders of BMO ETFs and unitholders of exchange-traded series of units of the BMO Mutual Funds (collectively, the "ETF Series")¹ that distribute monthly, as set out in the table below. Unitholders of record of the BMO ETFs and the ETF Series at the close of business on April 29, 2026, will receive cash distributions payable</description>
</item>
<item>
<title>Edreams Odigeo Sa: eDreams ODIGEO further Scales Agentic AI Ecosystem by Integrating Conversational Planning and Immediate Booking Fulfilment</title>
<link>https://6ix.com/company/edreams-odigeo-sa/news/edreams-odigeo-further-scales-agentic-ai-ecosystem-by-integrating-conversational-planning-and-immediate-booking-fulfilment</link>
<guid isPermaLink="true">https://6ix.com/company/edreams-odigeo-sa/news/edreams-odigeo-further-scales-agentic-ai-ecosystem-by-integrating-conversational-planning-and-immediate-booking-fulfilment</guid>
<pubDate>Wed, 22 Apr 2026 10:59:00 GMT</pubDate>
<description>BARCELONA, Spain, April 22, 2026--eDreams ODIGEO (the "Company" or "eDO") (BME: EDR) (OTC: EDDRF), the world’s leading travel subscription company and one of Europe’s largest e-commerce firms, today announced the latest advancement in its large suite of AI capabilities with the deployment of enhanced agentic capabilities. This represents the most recent updates in a decade-long cycle of continuous AI development, adding to a portfolio of proprietary technologies that allow eDO to deliver hyper-p</description>
</item>
<item>
<title>Jde Peets Nv: Coffee sector leaders launch industry-first global mapping initiative to accelerate the transition towards a deforestation-free coffee sector</title>
<link>https://6ix.com/company/jde-peets-nv/news/coffee-sector-leaders-launch-industry-first-global-mapping-initiative-to-accelerate-the-transition-towards-a-deforestation-free-coffee-sector</link>
<guid isPermaLink="true">https://6ix.com/company/jde-peets-nv/news/coffee-sector-leaders-launch-industry-first-global-mapping-initiative-to-accelerate-the-transition-towards-a-deforestation-free-coffee-sector</guid>
<pubDate>Wed, 22 Apr 2026 07:00:00 GMT</pubDate>
<description>PRESS RELEASE Amsterdam, April 22, 2026 The Coffee Canopy Partnership, initiated by JDE Peet’s (now part of Keurig Dr Pepper) was launched today to advance the identification and remediation of coffee-related deforestation. Developed in collaboration with leading coffee companies including JDE Peet's, Louis Dreyfus Company, Sucden, Neumann Kaffee Gruppe, Touton, Sucafina, and Tchibo, the Partnership will create the world's first comprehensive, openly-accessible map of global coffee production to</description>
</item>
<item>
<title>Ondine Biomedical Inc: Two Abstracts Accepted at World Congress</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/two-abstracts-accepted-at-world-congress</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/two-abstracts-accepted-at-world-congress</guid>
<pubDate>Wed, 22 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that two abstracts have been accepted for presentation at the 2026 World Congress on Infectious Diseases, highlighting eight-year longitudinal data on its light-activated antimicrobial technology. One abstract details a 66% reduction in Surgical Site Infections (SSIs) and sustained cost savings in spine surgery without resistance signals, while the second addresses limitations in infection control reporting. The company's CEO emphasized the sustained SSI reductio</description>
</item>
<item>
<title>Auction Technology Group Plc: Notification under UKLR 6.4.9R(2)</title>
<link>https://6ix.com/company/auction-technology-group-plc/news/notification-under-uklr-649r2-1</link>
<guid isPermaLink="true">https://6ix.com/company/auction-technology-group-plc/news/notification-under-uklr-649r2-1</guid>
<pubDate>Tue, 21 Apr 2026 08:37:00 GMT</pubDate>
<description>Auction Technology Group plc announced that its Chief Executive Officer, John-Paul Savant, has been appointed as a Non-Executive Director of Trustpilot Group plc, effective from the close of Trustpilot's Annual General Meeting on May 19, 2026. This disclosure is made in accordance with UKLR 6.4.9R(2).
Disclaimer*</description>
</item>
<item>
<title>Sinch Ab: Sinch named 2026 Adobe Customer Experience Orchestration Technology Partner of the year</title>
<link>https://6ix.com/company/sinch-ab/news/sinch-named-2026-adobe-customer-experience-orchestration-technology-partner-of-the-year-1</link>
<guid isPermaLink="true">https://6ix.com/company/sinch-ab/news/sinch-named-2026-adobe-customer-experience-orchestration-technology-partner-of-the-year-1</guid>
<pubDate>Tue, 21 Apr 2026 06:43:00 GMT</pubDate>
<description>Sinch today announced it has been named the 2026 Adobe Customer Experience Orchestration Technology Partner of the year. This recognition underscores Sinch's continued leadership in helping brands deliver connected, real-time customer experiences.</description>
</item>
<item>
<title>Elis Sa: Elis: Disclosure of trading in own shares occured from April 13 to April 17, 2026</title>
<link>https://6ix.com/company/elis-sa/news/elis-disclosure-of-trading-in-own-shares-occured-from-april-13-to-april-17-2026</link>
<guid isPermaLink="true">https://6ix.com/company/elis-sa/news/elis-disclosure-of-trading-in-own-shares-occured-from-april-13-to-april-17-2026</guid>
<pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
<description>Disclosure of trading in own shares occurred from April 13 to April 17, 2026 Puteaux, April 21, 2026 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from April 13 to April 17, 2026 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily total Volume (in</description>
</item>
<item>
<title>Auction Technology Group Plc: Directorate change</title>
<link>https://6ix.com/company/auction-technology-group-plc/news/directorate-change-789</link>
<guid isPermaLink="true">https://6ix.com/company/auction-technology-group-plc/news/directorate-change-789</guid>
<pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
<description>Auction Technology Group plc announced that Chief Executive Officer John-Paul Savant is stepping down after more than ten years, during which he oversaw the company's revenue growth from approximately $20 million to around $250 million in FY26. The Board is in the advanced stages of appointing a successor with strong commercial, operational, and marketplace leadership experience. The company stated that it has good strategic and trading momentum, which is expected to be maintained during the tra</description>
</item>
<item>
<title>Argen-x: argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP</title>
<link>https://6ix.com/company/argen-x/news/argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp</link>
<guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp</guid>
<pubDate>Sat, 18 Apr 2026 05:00:00 GMT</pubDate>
<description>ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 202</description>
</item>
<item>
<title>Oci Nv: OCI Global Publishes Notice of Annual General Meeting 2026</title>
<link>https://6ix.com/company/oci-nv/news/oci-global-publishes-notice-of-annual-general-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/oci-nv/news/oci-global-publishes-notice-of-annual-general-meeting-2026</guid>
<pubDate>Fri, 17 Apr 2026 17:50:00 GMT</pubDate>
<description>OCI Global (Euronext: OCI) ("OCI" or the "Company") today announces that it has published the notice and agenda for its Annual General Meeting ("AGM"), to be held on 2 June 2026.</description>
</item>
<item>
<title>Senzime Ab: Notice of Annual General Meeting in Senzime AB (publ)</title>
<link>https://6ix.com/company/senzime-ab/news/notice-of-annual-general-meeting-in-senzime-ab-publ-2</link>
<guid isPermaLink="true">https://6ix.com/company/senzime-ab/news/notice-of-annual-general-meeting-in-senzime-ab-publ-2</guid>
<pubDate>Fri, 17 Apr 2026 16:00:00 GMT</pubDate>
<description>Notice of Annual General Meeting in Senzime AB (publ).</description>
</item>
<item>
<title>Senzime Ab: Invitation to Presentations of Senzime's First Quarter 2026 Report</title>
<link>https://6ix.com/company/senzime-ab/news/invitation-to-presentations-of-senzimes-first-quarter-2026-report</link>
<guid isPermaLink="true">https://6ix.com/company/senzime-ab/news/invitation-to-presentations-of-senzimes-first-quarter-2026-report</guid>
<pubDate>Fri, 17 Apr 2026 08:20:00 GMT</pubDate>
<description>Invitation to Presentations of Senzime's First Quarter 2026 Report.</description>
</item>
<item>
<title>Ipsos Sa: Ipsos: Encouraging commercial momentum despite a slight decrease in organic growth in Q1</title>
<link>https://6ix.com/company/ipsos-sa/news/ipsos-encouraging-commercial-momentum-despite-a-slight-decrease-in-organic-growth-in-q1</link>
<guid isPermaLink="true">https://6ix.com/company/ipsos-sa/news/ipsos-encouraging-commercial-momentum-despite-a-slight-decrease-in-organic-growth-in-q1</guid>
<pubDate>Thu, 16 Apr 2026 15:45:00 GMT</pubDate>
<description>Encouraging commercial momentum despite a slight decrease in organic growth in Q1 Paris, April 16, 2026 – Ipsos, one of the world's leading market research and opinion polling companies, achieved revenue of €554.9 million in the first quarter of 2026. Total revenue growth stood at -2.4%, very strongly impacted by -5.4% unfavorable foreign exchange effects, related to the euro's appreciation against certain currencies, principally the US dollar. Organic growth was -1.4% and scope effects +4.3%, m</description>
</item>
<item>
<title>Fagron Nv: Pete Pharma and Fagron Enter Strategic Distribution Partnership to Expand Access to Pharmaceutical 3D Printing Across North America</title>
<link>https://6ix.com/company/fagron-nv/news/pete-pharma-and-fagron-enter-strategic-distribution-partnership-to-expand-access-to-pharmaceutical-3d-printing-across-north-america-1</link>
<guid isPermaLink="true">https://6ix.com/company/fagron-nv/news/pete-pharma-and-fagron-enter-strategic-distribution-partnership-to-expand-access-to-pharmaceutical-3d-printing-across-north-america-1</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>PHOENIX, April 16, 2026--Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D pharmaceutical printing, delivery systems, and scalable manufacturing platforms, today announced a strategic distribution and commercialization partnership with Fagron, Inc., a global leader in pharmaceutical compounding and personalized medicine.</description>
</item>
<item>
<title>Galderma Group N: Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-launches-new-alastin-regenerating-skin-nectar-with-trihextm-powered-by-its-next-generation-trihex-technologyr-regenerative-platform</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-launches-new-alastin-regenerating-skin-nectar-with-trihextm-powered-by-its-next-generation-trihex-technologyr-regenerative-platform</guid>
<pubDate>Thu, 16 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with </description>
</item>
<item>
<title>Valmet Oyj: Valmet reschedules its Interim Review January - March 2026 results webcast</title>
<link>https://6ix.com/company/valmet-oyj/news/valmet-reschedules-its-interim-review-january-march-2026-results-webcast-1</link>
<guid isPermaLink="true">https://6ix.com/company/valmet-oyj/news/valmet-reschedules-its-interim-review-january-march-2026-results-webcast-1</guid>
<pubDate>Wed, 15 Apr 2026 08:29:00 GMT</pubDate>
<description>Valmet has decided to reschedule the results webcast to 11:00 a.m. EEST instead of the previously communicated 10:00 a.m.</description>
</item>
<item>
<title>Havas Sa: Havas Maintains Its Positive Momentum With a Solid First Quarter, Reporting a Net Revenue Organic Growth of +2.5%</title>
<link>https://6ix.com/company/havas-sa/news/havas-maintains-its-positive-momentum-with-a-solid-first-quarter-reporting-a-net-revenue-organic-growth-of-25percent</link>
<guid isPermaLink="true">https://6ix.com/company/havas-sa/news/havas-maintains-its-positive-momentum-with-a-solid-first-quarter-reporting-a-net-revenue-organic-growth-of-25percent</guid>
<pubDate>Tue, 14 Apr 2026 15:45:00 GMT</pubDate>
<description>PARIS, April 14, 2026--Havas maintains its positive momentum with a solid first quarter, reporting a net revenue organic growth of +2.5%</description>
</item>
<item>
<title>Gnvr: Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline</title>
<link>https://6ix.com/company/gnvr/news/genvor-announces-strategic-memorandum-of-understanding-with-canlab-internationaltm-to-advance-commercial-peptide-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/gnvr/news/genvor-announces-strategic-memorandum-of-understanding-with-canlab-internationaltm-to-advance-commercial-peptide-pipeline</guid>
<pubDate>Tue, 14 Apr 2026 12:00:00 GMT</pubDate>
<description>Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline.</description>
</item>
<item>
<title>Valmet Oyj: Valmet to publish its Interim Review for January - March 2026 on April 28, 2026</title>
<link>https://6ix.com/company/valmet-oyj/news/valmet-to-publish-its-interim-review-for-january-march-2026-on-april-28-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/valmet-oyj/news/valmet-to-publish-its-interim-review-for-january-march-2026-on-april-28-2026-1</guid>
<pubDate>Tue, 14 Apr 2026 10:05:00 GMT</pubDate>
<description>Valmet's Interim Review January – March 2026 will be published on Tuesday, April 28, 2026, at approximately 9:00 a.m. Finnish time (EEST). The stock exchange release and presentation materials will be available on Valmet's website at www.valmet.com/investors.</description>
</item>
<item>
<title>Elis Sa: Elis: Disclosure of trading in own shares occured from April 7 to April 10, 2026</title>
<link>https://6ix.com/company/elis-sa/news/elis-disclosure-of-trading-in-own-shares-occured-from-april-7-to-april-10-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/elis-sa/news/elis-disclosure-of-trading-in-own-shares-occured-from-april-7-to-april-10-2026-1</guid>
<pubDate>Tue, 14 Apr 2026 06:00:00 GMT</pubDate>
<description>Disclosure of trading in own shares occurred from April 7 to April 10, 2026 Puteaux, April 14, 2026 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from April 7 to April 10, 2026 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily total Volume (in n</description>
</item>
<item>
<title>Ondine Biomedical Inc: Steriwave ICU Study Shows 39.5% Pneumonia Drop</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/steriwave-icu-study-shows-395percent-pneumonia-drop</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/steriwave-icu-study-shows-395percent-pneumonia-drop</guid>
<pubDate>Tue, 14 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that a peer-reviewed study published in Critical Care, conducted by the Royal Columbian Hospital Foundation, demonstrated a 39.5% reduction in pneumonia rates in ICU patients treated with Steriwave® nasal photodisinfection therapy, decreasing from 14.9 to 9.0 cases per 1000 ICU patient-days. While not powered for statistical significance on this outcome, the reduction was associated with a statistically significant decrease in early cumulative nasal pathogen burd</description>
</item>
<item>
<title>Jde Peets Nv: Keurig Dr Pepper Announces Results of Post-Closing Acceptance Period for Offer for JDE Peet’s - 97.75% of all Shares tendered</title>
<link>https://6ix.com/company/jde-peets-nv/news/keurig-dr-pepper-announces-results-of-post-closing-acceptance-period-for-offer-for-jde-peets-9775percent-of-all-shares-tendered</link>
<guid isPermaLink="true">https://6ix.com/company/jde-peets-nv/news/keurig-dr-pepper-announces-results-of-post-closing-acceptance-period-for-offer-for-jde-peets-9775percent-of-all-shares-tendered</guid>
<pubDate>Mon, 13 Apr 2026 21:00:00 GMT</pubDate>
<description>This is a joint press release by Keurig Dr Pepper Inc., Kodiak BidCo B.V. and JDE Peet’s N.V. pursuant to the provisions of Section 17, paragraph 4 of the Dutch Decree on public takeover bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the recommended public cash offer by Kodiak BidCo B.V. (the "Offeror") for all issued and outstanding ordinary shares in the capital of JDE Peet’s N.V. (such offer, the “Offer”, such shares, the “Shares” and each holder of such Shares, a “Sh</description>
</item>
<item>
<title>Jde Peets Nv: Keurig Dr Pepper Announces Results of Post-Closing Acceptance Period for Offer for JDE Peet's</title>
<link>https://6ix.com/company/jde-peets-nv/news/keurig-dr-pepper-announces-results-of-post-closing-acceptance-period-for-offer-for-jde-peets-1</link>
<guid isPermaLink="true">https://6ix.com/company/jde-peets-nv/news/keurig-dr-pepper-announces-results-of-post-closing-acceptance-period-for-offer-for-jde-peets-1</guid>
<pubDate>Mon, 13 Apr 2026 21:00:00 GMT</pubDate>
<description>Keurig Dr Pepper Inc. ("KDP") (NASDAQ: KDP) and JDE Peet's N.V. ("JDE Peet's") (EURONEXT: JDEP) jointly announce that the post-closing acceptance period relating to the Offer (the "Post-Closing Acceptance Period") expired today at 17:40 hours CEST. During the Post-Closing Acceptance Period, 7,821,867 Shares have been tendered under the Offer, representing approximately 1.61% of the Shares and an aggregate value of approximately EUR 249,126,463.95. Together with the 466,712,270 Shares that were a</description>
</item>
<item>
<title>Pandora A/s: Pandora reduces treasury shares to less than 5% of share capital</title>
<link>https://6ix.com/company/pandora-as/news/pandora-reduces-treasury-shares-to-less-than-5percent-of-share-capital</link>
<guid isPermaLink="true">https://6ix.com/company/pandora-as/news/pandora-reduces-treasury-shares-to-less-than-5percent-of-share-capital</guid>
<pubDate>Mon, 13 Apr 2026 10:42:00 GMT</pubDate>
<description>In accordance with Section 31 of the Capital Market Act, it is hereby announced that Pandora A/S as of today owns a total of 199,368 treasury shares of nominally DKK 1, hence less than 5% of the total share capital and the total voting rights in the Company. The decrease in number of treasury shares is a consequence of the share capital reduction resolved by the Company’s Annual General Meeting on 11 March 2026, which was effected on 10 April, 2026 cf. Company announcement no. 1010. ABOUT PANDOR</description>
</item>
<item>
<title>Ondine Biomedical Inc: Business Update</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/business-update-129</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/business-update-129</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. reported a 29% unaudited revenue growth in 2025 and has completed patient enrollment in its pivotal LANTERN Phase 3 U.S. trial, with results anticipated in Spring 2026. The company is expanding its real-world evidence through SSI reduction programs and has initiated in-house manufacturing upgrades to support future growth and enhance supply chain control. Significant investments in facility upgrades and automation equipment are underway to improve operational efficacy and </description>
</item>
<item>
<title>Fagron Nv: Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026</title>
<link>https://6ix.com/company/fagron-nv/news/fagron-convenes-ordinary-and-extraordinary-general-meeting-on-11-may-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/fagron-nv/news/fagron-convenes-ordinary-and-extraordinary-general-meeting-on-11-may-2026-1</guid>
<pubDate>Fri, 10 Apr 2026 05:00:00 GMT</pubDate>
<description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its shareholders and holders of subscription rights to attend its Ordinary General Meeting and Extraordinary General Meeting, to be held on Monday, 11 May 2026, starting at 15:00 CEST. The Extraordinary General Meeting will be held before notary and will take place immediately following the Ordinary General Meet</description>
</item>
<item>
<title>Edgemont Gold Corp: Edgemont Gold Provides Update on Transaction with Laiva Gold</title>
<link>https://6ix.com/company/edgemont-gold-corp/news/edgemont-gold-provides-update-on-transaction-with-laiva-gold</link>
<guid isPermaLink="true">https://6ix.com/company/edgemont-gold-corp/news/edgemont-gold-provides-update-on-transaction-with-laiva-gold</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 10, 2026) - Edgemont Gold Corp. (CSE: EDGM) (the "Company" or "Edgemont") is pleased to provide an update o</description>
</item>
<item>
<title>Cardinal Ethanol Llc: Vault 44.01 to Construct First CCS Project in Indiana with EPA Class VI Permit Approval</title>
<link>https://6ix.com/company/cardinal-ethanol-llc/news/vault-4401-to-construct-first-ccs-project-in-indiana-with-epa-class-vi-permit-approval</link>
<guid isPermaLink="true">https://6ix.com/company/cardinal-ethanol-llc/news/vault-4401-to-construct-first-ccs-project-in-indiana-with-epa-class-vi-permit-approval</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>Vault 44.01 Ltd. ("Vault"), a market leader in the development of carbon capture and sequestration (CCS) projects, today announced that the U.S. Environmental Protection Agency (EPA) Region 5 has issued a final Underground Injection Control (UIC) Class VI permit for the One Carbon Partnership CCS project near Union City, Indiana (the "OCP Project"). One Carbon Partnership is a joint venture between Cardinal Ethanol and Vault.</description>
</item>
<item>
<title>Senzime Ab: Senzime Secures Strategic Hospital Orders Within Leading US Integrated Healthcare Delivery Network</title>
<link>https://6ix.com/company/senzime-ab/news/senzime-secures-strategic-hospital-orders-within-leading-us-integrated-healthcare-delivery-network</link>
<guid isPermaLink="true">https://6ix.com/company/senzime-ab/news/senzime-secures-strategic-hospital-orders-within-leading-us-integrated-healthcare-delivery-network</guid>
<pubDate>Thu, 09 Apr 2026 12:10:00 GMT</pubDate>
<description>Senzime Secures Strategic Hospital Orders Within Leading US Integrated Healthcare Delivery Network.</description>
</item>
<item>
<title>Edreams Odigeo Sa: eDreams ODIGEO Expands International Footprint With Subscription Service in South Africa Following Proven Market Success</title>
<link>https://6ix.com/company/edreams-odigeo-sa/news/edreams-odigeo-expands-international-footprint-with-subscription-service-in-south-africa-following-proven-market-success</link>
<guid isPermaLink="true">https://6ix.com/company/edreams-odigeo-sa/news/edreams-odigeo-expands-international-footprint-with-subscription-service-in-south-africa-following-proven-market-success</guid>
<pubDate>Thu, 09 Apr 2026 11:12:00 GMT</pubDate>
<description>BARCELONA, Spain, April 09, 2026--eDreams ODIGEO (the "Company" or "eDO") (BME: EDR) (OTC: EDDRF), the world’s leading travel subscription platform, today announced the scaling of its Prime subscription offering in South Africa, moving the region into a phase of full-scale expansion.</description>
</item>
<item>
<title>Fagron Nv: Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth</title>
<link>https://6ix.com/company/fagron-nv/news/fagron-reports-solid-first-quarter-revenue-of-euro263-million-reflecting-10percent-topline-growth-1</link>
<guid isPermaLink="true">https://6ix.com/company/fagron-nv/news/fagron-reports-solid-first-quarter-revenue-of-euro263-million-reflecting-10percent-topline-growth-1</guid>
<pubDate>Thu, 09 Apr 2026 05:00:00 GMT</pubDate>
<description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER1), supported by incremental M&A contribution and outstanding performance in Latin America</description>
</item>
</channel>
</rss>